Nonalcoholic steatohepatitis (NASH) therapies with prospective launches post-2020 will likely have reimbursement challenges...
Future NASH reimbursement issues may echo HCV therapies
Nonalcoholic steatohepatitis (NASH) therapies with prospective launches post-2020 will likely have reimbursement challenges mirroring those faced by hepatitis C (HCV) therapies approved five years ago, experts said.
Biopharmaceuticals and Liposomal Formulations
Polymun offers the development of liposomal formulations for all kinds of pharmaceutically active ingredients and vaccine antigens. A broad spectrum of analytical methods has been established for this purpose.
Bristol-Myers and Vedanta to study combination therapy for cancer
Bristol-Myers Squibb has partnered with PureTech Health subsidiary Vedanta Biosciences to study its Opdivo in combination with VE800 drug candidate for the treatment of advanced or metastatic cancers.
AstraZeneca and Cancer Research UK open functional genomics centre
AstraZeneca has partnered with Cancer Research UK to open a functional genomics centre of excellence focused on accelerating the discovery and development of new oncology medicines.
Novo Nordisk and e-therapeutics alliance to focus on type-2 diabetes
Novo Nordisk has entered into research collaboration with UK-based e-therapeutics for the development of new treatment strategies for a specific area of type-2 diabetes.
Allergan’s Phase III Botox trial for depression pushed to H2 2019
Allergan’s Botox (onabotulinumtoxin A) Phase III trial in major depressive disorder (MDD) is slated to initiate in the second half of 2019 (2H19), said a company spokesperson.
Foamix’s rosacea drug FMX103 splits views on sunburn risk
Foamix Pharmaceuticals’ FMX103 (1.5% topical minocycline foam) has experts split over the drug’s real-world ability to protect against sunburn, despite expected FDA approval for moderate-to-severe facial papulopustular rosacea.
Is China the next great hope for the pharma industry?
Many top pharma firms have been forced to drop prices to get a slice of the Chinese market, but that hasn’t dampened spirits one bit – on the contrary, CEOs from companies like AstraZeneca and Pfizer have been celebrating dramatic Chinese sales increases in 2018. So how is China’s pharmaceutical market growing and is it really a clean bill of health for any internationals lining up to profit?
CEPI and Imperial College London collaborate on Disease X vaccines project
The Coalition for Epidemic Preparedness Innovations (CEPI) in Norway and Imperial College London have formed an alliance to develop new vaccines against known as well as unknown pathogens, which are commonly referred to as Disease X.
Merck partners with Cyclica for AI-based screening of drug targets
Merck has signed an agreement to licence Canada-based Cyclica’s cloud-based in-silico proteome screening platform called Ligand Express to support its research efforts.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.